Sign Up to like & get
recommendations!
1
Published in 2019 at "Haemophilia"
DOI: 10.1111/hae.13853
Abstract: BAY 94‐9027 is an extended‒half‐life, site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII). The PROTECT VIII main study demonstrated efficacy of bleed control using extended‐interval prophylaxis with BAY 94‐9027 for 36 weeks.
read more here.
Keywords:
bay 9027;
efficacious well;
9027 prophylaxis;
protect viii ... See more keywords